World Congress of Nephrology 2013

Abstract Number: 451327

Correspondence/Presenting Author: Udom Krairittichai

Department/Institution: Department of Medicine, Rajavithi Hospital, Department of Medical Services, College of Medicine, Rangsit University,

Address: 2 Rajavithi road, Rajdhvei

City/State/Zip/Country: Bangkok, 10400, Thailand

Phone: 66818146210 Fax: 6623548188 E-mail: krairit@yahoo.com

Abstract Category: Infection (CKD and ESKD)


Travel Grant: No, I am not applying for the WCN 2013 Travel Grant.

ISN Awards: Not yet indicated

ISN Global Outreach (GO) Program:

I confirm that this abstract is linked to a ISN GO activity: No

Transparency Declaration: NO, I have nothing to disclose.

Organ Trafficking and Tourism Ethics Compliance: I submit that the author(s)/scientist(s) of this abstract have not violated any aspect of the DOI and that this research conforms with the ethical statements as noted.

Presentation: Moderated Posters

Title: Efficacy of the Trivalent Influenza Vaccination in Thai Patients with Hemodialysis or Kidney Transplant Compared with Healthy Volunteers

Udom Krairittichai¹ and Malinee Chittaganpitch². ¹Department of Medicine, Rajavithi Hospital, Department of Medical Services, College of Medicine, Rangsit University, Bangkok, Thailand and ²Respiratory virus section, National Institute of Health, Department of Medical Sciences, Nontaburi, Thailand.

INTRODUCTION AND AIMS: An outbreak of Influenza A especially the H1N1 viral strain caused high morbidity and mortality. A new trivalent Influenza vaccine includes antigens from the 2009 pandemic H1N1 Influenza A, seasonal Influenza A and Influenza B. However, the efficacy of the vaccine in patients with HD or KT has been uncertain. The purpose of the present study was to evaluate the immune response to trivalent Influenza vaccination in Thai patients with HD or KT compared with healthy volunteers.

METHODS: This was a cross-sectional study in Thai healthy volunteers and patients with HD and
KT who received the trivalent influenza vaccine provided by the Ministry of Public Health of Thailand from 1 November 2011 to 31 December 2011. Each subject was injected intramuscularly with one dose (0.5 milliliter) of trivalent influenza vaccine containing viral strains recommended by the WHO for the 2011 influenza season (southern hemisphere). Blood samples before and 6 weeks after the vaccination were measured for immune response using a hemagglutination-inhibition antibody assay.

RESULTS: Subjects consisted of 30 healthy volunteers, 30 patients with HD and 30 patients with KT. Prevalence of pre-vaccination seroprotective (SP) immunity in each group (healthy volunteers, HD, KT) was as follows: against H1N1 (33.3%: 23.3%: 10.0%), H3N2 (80.0%: 26.7%: 23.3%) and B (60.0%: 20.0%: 3.3%) viral strains, respectively. Those who were seronegative (SN) before testing positive after one dose of this vaccine were as follows: H1N1 (100.0%: 73.9%: 74.1%), H3N2 (66.7%: 86.4%: 34.8%) or B (58.3%: 66.7%: 48.3%) viral strains, respectively. The healthy group showed significantly higher SP immune response for H1N1 than the HD and KT groups (p=0.023). The HD group had significantly higher SP immune response for H3N2 than the KT groups (p=0.001). Immune responses for the B vaccine in all groups were not different. No major adverse event was found in any group.

CONCLUSIONS: Immune response for H1N1 vaccine in the HD and KT groups was slightly less than that of the healthy group. Immune response for H3N2 vaccine in the KT groups was less than in the healthy and HD groups. Immune responses for B vaccine in all groups were not different.